Triple Negative Breast Neoplasms: all 1,163 studies
Page 2 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingNCT07318805Phase 1
- Phase 1 Study of CLR 125 in Triple Negative Breast CancerRecruitingNCT07311993Phase 1
- Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNot yet recruitingNCT07300475Phase 1
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingNCT07299409Phase 2
- GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid TumoursRecruitingNCT07297667Phase 1
- Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)RecruitingNCT07283692Phase 2
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerRecruitingNCT07281976Phase 1/2
- Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast CancerRecruitingNCT07276880Phase 2
- A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.Not yet recruitingNCT07272642Phase 1
- TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast CancerNot yet recruitingNCT07271992Phase 2
- Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsRecruitingNCT07261631Phase 1
- Organoids From Breast Cancer Patients Treated With Neoadjuvant TherapyRecruitingNCT07260188
- The TASTY-steering StudyRecruitingNCT07258563Not applicable
- Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast CancerNot yet recruitingNCT07256964Phase 2
- Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry AnalysisNot yet recruitingNCT07246759
- Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNot yet recruitingNCT07244874Phase 2
- A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07229313Phase 1
- A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4Enrolling by invitationNCT07218003Phase 1
- Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast CancerNot yet recruitingNCT07217990Phase 1/2
- Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesRecruitingNCT07211178
- A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)RecruitingNCT07208149Phase 1/2
- PQ203 in Advanced Malignant Tumors Including Triple Negative Breast CancerRecruitingNCT07190469Phase 1
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRecruitingNCT07189871Phase 1/2
- Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast CancerRecruitingNCT07188246Phase 2
- The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and PaclitaxelNot yet recruitingNCT07187674Not applicable
- A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsRecruitingNCT07182149Phase 1
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingNCT07178730Phase 3
- A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCRecruitingNCT07178171Phase 1
- Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast CancerNot yet recruitingNCT07161791Phase 1/2
- Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast CancerNot yet recruitingNCT07153965Phase 2
- Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingNCT07151586Phase 2
- Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast CancerNot yet recruitingNCT07139470Phase 1/2
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingNCT07137416Phase 1
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRecruitingNCT07115043Phase 1/2
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast CancerRecruitingNCT07111832Phase 3
- BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast CancerRecruitingNCT07108309Phase 2
- Triple Negative Breast Cancer and Celecoxib. Pilot StudyRecruitingNCT07104266Phase 2
- A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).Not yet recruitingNCT07101614Phase 2
- Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer EvolutionRecruitingNCT07084571
- SC-101 in Subjects With Advanced NECTIN4-Amplified CancersNot yet recruitingNCT07080619Phase 2
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast CancerRecruitingNCT07078604Phase 2
- Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdRecruitingNCT07073755
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingNCT07069595Phase 2
- A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)RecruitingNCT07067138Not applicable
- Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBCRecruitingNCT07066189Not applicable
- Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced MalignanciesRecruitingNCT07064018Phase 1/2
- A Study of LY4175408 in Participants With Advanced CancerRecruitingNCT07046923Phase 1
- Trop-2 Targeted PET Probes in Advanced TNBCRecruitingNCT07046455Not applicable
- JS207 Combination Therapy in Triple-negative Breast CancerRecruitingNCT07045311Phase 2
- A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCNot yet recruitingNCT07040644Phase 2
- A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsRecruitingNCT07029399Phase 1
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsRecruitingNCT07020117Phase 1
- Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast CancerRecruitingNCT07017673Phase 2
- Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCRecruitingNCT07016399Phase 2
- ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNot yet recruitingNCT07015853Phase 2
- Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBCNot yet recruitingNCT07011823Phase 2
- Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)RecruitingNCT07011654Phase 1/2
- Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBCNot yet recruitingNCT07007780Phase 2
- Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasRecruitingNCT06999187Phase 1
- Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast CancerNot yet recruitingNCT06977542Phase 2
- Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast CancerRecruitingNCT06976944Phase 2
- Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without ImmunotherapyNot yet recruitingNCT06976021Phase 2
- Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT06975644Not applicable
- Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DMRecruitingNCT06974604Phase 2
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3
- Saci Nivo Rela for TNBCRecruitingNCT06963905Phase 1/2
- Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer PatientsRecruitingNCT06962163Not applicable
- Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBCRecruitingNCT06955156Phase 2
- Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingNCT06954480Phase 2
- A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerRecruitingNCT06926920Phase 1/2
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RecruitingNCT06926868Phase 2/3
- Viscum Album for TNBC on Adjuvant PembrolizumabRecruitingNCT06920810Phase 4
- Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）Enrolling by invitationNCT06910072Phase 2/3
- A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCsRecruitingNCT06908928Phase 1
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
- A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.RecruitingNCT06889610Phase 2
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) ProductsEnrolling by invitationNCT06885424
- Circadian Rhythm Impact on TNBC Response to Neoadjuvant ImmunotherapyRecruitingNCT06880029Phase 1/2
- Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast CancerRecruitingNCT06879704Not applicable
- A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast CancerRecruitingNCT06878625Phase 2
- The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.RecruitingNCT06851299Phase 2
- HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
- NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer PatientsRecruitingNCT06845319Phase 2
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast CancerRecruitingNCT06831955Phase 2
- SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast CancerNot yet recruitingNCT06819319Phase 2
- Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBCRecruitingNCT06817525Phase 2
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerRecruitingNCT06802757Phase 2
- First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerRecruitingNCT06799065Phase 1/2
- Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast CancerNot yet recruitingNCT06798506
- Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer PatientsNot yet recruitingNCT06795503Phase 3
- BrAin Metastasis in TripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCRecruitingNCT06793332Phase 2
- Capecitabine in Low Risk Triple Negative Breast CancerRecruitingNCT06787339Phase 2
- QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingNCT06786026Phase 2
- Prospective Registry of ADC as First- and Second-line Treatment for Breast CancerRecruitingNCT06774027
- Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast CancerRecruitingNCT06768931Phase 2
- AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerRecruitingNCT06767527Phase 3
- A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast CancerNot yet recruitingNCT06746870Phase 2
- NearWave Optical Molecular MonitoringRecruitingNCT06744465Not applicable